by The global immunotherapy drugs market was valued at approximately USD 176.94 million in 2021 to US$ 351.56 billion by 2030 and is anticipated to grow at compounded annual growth rate (CAGR) of 7.9% from 2021 to 2030, as per reports by market research and consulting organization Precedence Research.
The report contains 150+ pages with detailed analysis. The base year for the study has been considered 2021, the historic year 2017 to 2020, the forecast period considered is from 2021 to 2030.
The immunotherapy drugs market is analyzed on the basis of value (US$ Million), volume (Unit), and price (US$/Unit). The report offers exclusive insights to help companies make informed decisions to sustain growth through the assessment period.
Download Free Sample Copy with TOC, Graphs & List of Figures @ https://www.precedenceresearch.com/sample/1472
The rising prevalence of chronic diseases, rising healthcare expenditure, and growing adoption of the targeted therapy among the population are the major factors that propels the growth of the global immunotherapy drugs market. The growing popularity of the biosimilars owing to the approvals received by certain biosimilar drugs from the authorities like FDA and EMA is expected to be an important driving factor in the forthcoming years.
The growing investments in the research and development by the biotechnology and pharmaceutical companies, rising number of research labs, and growing research collaborations by the key market players are the several crucial factors that are expected to have a significant impact on the market growth during the forecast period. The rapidly growing biopharmaceutical industry owing to the rising government support and rising corporate investments will augment the growth of the immunotherapy drugs market. Furthermore, the rising awareness regarding the benefits of the immunotherapy drugs over the traditional treatment procedures is significantly spurring the demand for the immunotherapy drugs.
Scope of the Immunotherapy Drugs Market
| Report Coverage | Details |
| Market Size in 2021 | US$176.94 Billion |
| Growth Rate From 2021 to 2030 | 7.9% |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Segments Covered | Drug, Therapeutic Area, Region |
Competitive Intelligence
The report provides an understanding of the market composition and explains the role of established players and regional contributors. It is essential for the market players to make calculative moves and focus on client acquisition and retention. The detailed company profiles will provide the necessary intelligence to the reader. In order to maintain their share, the market players are focusing on strategies such as cross-border expansion, product differentiation and so on.
Some of the prominent players in the global immunotherapy drugs market are listed as below:
- F. Hoffmann-La Roche AG
- GlaxoSmithKline plc.
- AbbVie, Inc.
- Amgen, Inc.
- Merck & Co., Inc.
- Alligator Bioscience
- UbiVac
- Bristol-Myers Squibb
- Novartis International AG
- AstraZeneca plc
COVID-19 Impact Analysis:
- Lockdowns caused disruptions in transportation and logistics
- Social distancing and restrictions severely disrupted businesses and operations
- Supply impacts were further compounded owing to reduced disposable income
- Impacted manufacturing activities and mining operations globally
- Took a toll on economy of various countries
- Caused sudden and drastic downturn in economic activity
- Disrupted agriculture, fisheries, dairy,and other sectors
- Caused loss of employment and financial crisis
- Emergence of variants continue to cause concerns and impact normal routines
Market Dynamics:
Steady revenue growth of the global immunotherapy drugs market is attributed to factors such as rising prevalence of cancer across the globe, growing burden of infectious and autoimmune diseases, rising awareness of the advantages of immunotherapy drugs over conventional treatments methods, and increasing demand for advanced biologics and biosimilars. As per a study conducted by the National Cancer Institute, there were approximately 1,806,590 new cancer diagnoses and 606,520 deaths caused by cancer in the United States in 2020.
Increasing applications of monoclonal antibodies in immunotherapy drugs due to their high specificity and effectiveness, increasing cancer research activities, unprecedented rise in demand for vaccines worldwide amid the ongoing COVID-19 pandemic, and growing need for advanced therapeutics for chronic and acute infectious and autoimmune diseases are other key factors expected to drive the global market revenue growth.
Market Segmentation
By Drug Type
- Monoclonal Antibodies
- Vaccines
- Interleukins
- Interferons Alpha & Beta
- Others
By Therapeutic Area
- Cancer
- Infectious Diseases
- Autoimmune & Inflammatory Diseases
- Others
Regional Segmentation
– North America (U.S. and Canada)
– Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
– Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
– Latin America (Brazil and Rest of Latin America)
– Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
Why should you invest in this report?
If you are aiming to enter the global immunotherapy drugs market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for immunotherapy drugs are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2030 so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Buy Full Research Report, Click Here@ https://www.precedenceresearch.com/checkout/1472
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Immunotherapy Drugs Market
5.1. COVID-19 Landscape: Immunotherapy Drugs Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Immunotherapy Drugs Market, By Drug
8.1. Immunotherapy Drugs Market, by Drug Type, 2021-2030
8.1.1. Monoclonal Antibodies
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Vaccines
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Interleukins
8.1.3.1. Market Revenue and Forecast (2019-2030)
8.1.4. Interferons Alpha & Beta
8.1.4.1. Market Revenue and Forecast (2019-2030)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Immunotherapy Drugs Market, By Therapeutic Area
9.1. Immunotherapy Drugs Market, by Therapeutic Area, 2021-2030
9.1.1. Cancer
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Infectious Diseases
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Autoimmune & Inflammatory Diseases
9.1.3.1. Market Revenue and Forecast (2019-2030)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Immunotherapy Drugs Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Drug (2019-2030)
10.1.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Drug (2019-2030)
10.1.3.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Drug (2019-2030)
10.1.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Drug (2019-2030)
10.2.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Drug (2019-2030)
10.2.3.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Drug (2019-2030)
10.2.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Drug (2019-2030)
10.2.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Drug (2019-2030)
10.2.6.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Drug (2019-2030)
10.3.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Drug (2019-2030)
10.3.3.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Drug (2019-2030)
10.3.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Drug (2019-2030)
10.3.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Drug (2019-2030)
10.3.6.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Drug (2019-2030)
10.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Drug (2019-2030)
10.4.3.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Drug (2019-2030)
10.4.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Drug (2019-2030)
10.4.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Drug (2019-2030)
10.4.6.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Drug (2019-2030)
10.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Drug (2019-2030)
10.5.3.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Drug (2019-2030)
10.5.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
Chapter 11. Company Profiles
11.1. F. Hoffmann-La Roche AG
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. GlaxoSmithKline plc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. AbbVie, Inc.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Amgen, Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Merck & Co., Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Alligator Bioscience
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. UbiVac
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Bristol-Myers Squibb
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Novartis International AG
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. AstraZeneca plc
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Purchase Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1472
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
